文献速递慢性肾脏病血液净化与透析

晚期慢性肾脏病过渡至透析患者的泻药使用情况

Laxative use in patients with advanced chronic kidney disease transitioning to dialysis.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

该回顾性队列纳入102 477例过渡至透析的美国退伍军人,分析过渡前后36个月内每6个月任一泻药处方填充比例,并采用多变量logistic回归识别透析前1年泻药使用的相关因素。结果显示泻药使用比例随接近终末期肾病而升高,过渡后6个月内达峰值37.1%,之后保持稳定。

要点

  • 泻药处方比例随接近终末期肾病而升高,过渡后6个月内峰值37.1%。
  • 泻药使用者中最常用的是粪便软化剂(约30%),其次为高渗剂(约20%)。
  • 抗凝药、口服铁剂、非阿片类镇痛药、抗组胺药和阿片类镇痛药与透析前泻药使用独立相关。

核心结论

  • 随着患者接近终末期肾病过渡,泻药使用显著增加,可能反映过渡期药物性便秘负担加重。

研究设计与样本

  • 回顾性队列研究,纳入2007年10月至2015年3月间过渡至透析的102 477例美国退伍军人。
  • 分析过渡前后36个月内每6个月任一泻药处方填充比例,并以多变量logistic回归识别透析前1年泻药使用的相关因素。

主要发现

  • 泻药处方比例随进展至终末期肾病而升高,在过渡后6个月内达峰值37.1%,之后在整个过渡后时期保持相对稳定。
  • 泻药使用者中,粪便软化剂最常用(约30%),其次为高渗剂(约20%)、刺激性泻药(约10%)、膨胀性泻药(约3%)、氯通道激活剂(<1%)及几种联合用药。
  • 抗凝药、口服铁剂、非阿片类镇痛药、抗组胺药和阿片类镇痛药是透析前泻药使用的独立相关因素。

临床怎么用

  • 临床应关注晚期CKD过渡至透析患者的便秘管理,尤其在使用抗凝药、铁剂、镇痛药、抗组胺药或阿片类药物时。
  • 泻药使用增加可能反映药物性便秘负担,优化上述药物使用或有助于减少泻药需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Constipation is highly prevalent in patients with chronic kidney disease (CKD), particularly among those with end-stage renal disease (ESRD), partly due to their dietary restrictions, comorbidities and medications. Laxatives are typically used for constipation management; however, little is known about laxative use and its associated factors in patients with advanced CKD transitioning to ESRD. METHODS: In a retrospective cohort of 102 477 US veterans transitioning to dialysis between October 2007 and March 2015, we examined the proportion of patients who filled a prescription for any type of laxative within each 6-month period over 36 months pre- and post-transition to ESRD. Factors associated with laxative use during the last 1-year pre-ESRD period were identified by multivariable logistic regression. RESULTS: The proportion of patients prescribed laxatives increased as patients progressed to ESRD, peaking at 37.1% in the 6 months immediately following ESRD transition, then remaining fairly stable throughout the post-ESRD transition period. Among laxative users, stool softeners were the most commonly prescribed (∼30%), followed by hyperosmotics (∼20%), stimulants (∼10%), bulk formers (∼3%), chloride channel activator (<1%) and several combinations of these. The use of anticoagulants, oral iron supplements, non-opioid analgesics, antihistamines and opioid analgesics were among the factors independently associated with pre-ESRD laxative use. CONCLUSION: The use of laxatives increased considerably as patients neared transition to ESRD, likely mirroring the increasing burden of drug-induced constipation during the ESRD transition period. Findings may provide novel insight into better management strategies to alleviate constipation symptoms and reduce medication requirements in patients with advanced CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Sumida K, Dashputre AA, Potukuchi PK, et al. Laxative use in patients with advanced chronic kidney disease transitioning to dialysis. Nephrol Dial Transplant. 2021. PMID: 33035325. doi:10.1093/ndt/gfaa205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。